Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19


COVID
Credit: CC0 Public Domain

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could—if given early enough—potentially reduce the risk of death from the most serious complication of Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection.

Prazosin, a U.S. Food and Drug Administration-approved alpha blocker that relaxes , may specifically target an extreme inflammatory process often referred to as cytokine storm syndrome (CSS) that disproportionately affects older adults with underlying , and is associated with disease severity and increased risk of death in COVID-19 infection. Using it pre-emptively to address COVID-19-associated hyperinflammation of the lungs and other organs has the potential to reduce deaths in the most vulnerable populations, they say.

In a report of their findings published April 30 in the Journal of Clinical Investigation, the researchers caution that although they believe if given early enough after viral exposure, the could prevent some deaths, it would not work in patients with advanced stages of the disease. They also emphasize that controlled clinical trials for this novel use of prazosin are needed before it can be safely recommended.

The investigators published the letter, they said, in hopes of stimulating rapid efforts to conduct such trials.

In the letter, the researchers described how they have been working in collaboration with researchers in the Johns Hopkins Divisions of Rheumatology and Infectious Diseases, and Departments of Neurology and Neurosurgery, to identify chemical ways of safely blocking the actions of catecholamines and cytokine responses. Together, catecholamines and cytokines enhance the inflammatory process that leads to severe COVID-19 symptoms, explains Chetan Bettegowda, M.D., Ph.D., Jennison and Novak Families Professor of Neurosurgery, who is senior author of the paper.

“The purpose of our article is to make the biomedical community aware of the potential of this approach and to stimulate additional basic and . Although, we are excited about this idea, we stress that a clinical trial is necessary to know if this intervention will help COVID patients, and that is where we are focusing all of our attention,” says Bettegowda.

In mouse models of CSS, they found that prazosin—commonly used to treat blood pressure, prostate gland enlargement and other conditions—blocked catecholamines (hormones released by the adrenal glands when the body is under stress), reduced cytokine levels, and increased survival after exposure to agents that trigger cytokine storm responses similar to those observed in COVID-19.

Drugs that target CSS have been found to reduce the risk of death from other viral illnesses by up to 55%, according to preliminary results from a retrospective clinical study.

Prazosin is taken by mouth, costs less than $25 per month in the United States, and has been safely taken by millions of people over the last two decades. This should enable highly expedited clinical trials in people early after exposure to the SARS-CoV-2 virus, say the researchers.

“All drugs can have unanticipated side effects when used in new situations, so it is critical to evaluate the effectiveness and side effects of this drug in controlled before it can be safely recommended for public use. This is particularly important for drugs like prazosin, which are already sold in pharmacies,” says Bettegowda.

Maximilian Konig, M.D., research fellow and lead author of the report, says a vaccine remains the best long-term hope to prevent deaths from COVID-19 but notes, at present, there are hundreds of individuals throughout the world who are dying every day. “Prazosin is already widely available, known to be safe and inexpensive, and the regulatory path for use in individuals exposed to the virus is straightforward,” he says.

The CSS treatment was granted Food and Drug Administration approval to be studied in a clinical trial for individuals with COVID-19.


Follow the latest news on the coronavirus (COVID-19) outbreak


More information:
Maximilian F. Konig et al, Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists, Journal of Clinical Investigation (2020). DOI: 10.1172/JCI139642

Citation:
Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19 (2020, May 19)
retrieved 19 May 2020
from https://medicalxpress.com/news/2020-05-urge-clinical-trial-blood-pressure.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



loading...

Related posts:

Newborn may have contracted coronavirus in the womb
For young health care worker, stroke 'Didn't even occur to me'
Aldosterone production is a common and unrecognized cause of high blood pressure
Zi-Studie zur Inanspruchnahme der Darmkrebsfrüherkennung veröffentlicht
Klappenersatz bei Aortenstenose: Neue Erkenntnisse über den Behandlungserfolg von TAVI
Virus 'eminently capable' of spreading through speech: study
Spain govt seeks 2-week extension of lockdown
New York's daily virus death toll falls below 100: governor
Mortality rates hint at even higher coronavirus death toll
First prospective study of critically ill COVID-19 patients in NYC
What can a COVID-19 antibody test tell me?
Live poultry linked to Salmonella cases in 28 states
Mediziner fordern vollständige Öffnung von Schulen und Kitas
To become happy, people need enough time... But how much is enough?
Nearly half of Moroccans 'anxious' under lockdown: study
Deutsche Zigarettenautomaten könnten Fall für den EuGH werden
Schwangerschaft: "Natürlich" bedeutet nicht automatisch gesund
US begins crackdown on unvetted virus blood tests
Insomnia may forecast depression, thinking problems in older people
Researchers link gene mutation to autism behaviors
the hunt for the antibody to treat COVID-19
COVID-19 und der neue Alltag mit Maske: Welche sind wofür geeignet?
UK adds loss of taste and smell to coronavirus symptoms
Funktion des Nierenfilters geklärt - Biermann Medizin
Sozioökonomische Faktoren beeinflussen Lebensqualität nach einer Herzoperation
COVID-19 disruption will lead to 28 million surgeries cancelled worldwide
SARS-CoV-2-PCR-Tests erreichen Rekordniveau – Zahl der Antikörpertests steigt
Deutsche Dermatologische Gesellschaft e.V. - Aktuelles zu COVID-19
WHO: Corona-Ansteckung durch Berührung von Oberflächen nicht bewiesen
Some recommended cardiovascular medications prescribed less frequently to women
Iran says virus deaths close to 7,000
Cord blood study provides insights on benefits, limitations for autism treatment
Endgültiges Aus für Mentholzigarette in der EU
Interdisziplinäre zentrale Ultraschalleinheit des UKL als Ausbildungsstätte anerkannt
Ärzte-Statistik: 402.000 Ärzte in Deutschland
First-of-its-kind-study reveals that eating prior to cardiac catheterization is non-inferior to fast
Hemmung zelleigenen Enzyms: Strategie für Entwicklung antiviraler Breitbandwirkstoffe
COVID-19 könnte bei Kindern schwere Entzündungserkrankung verursachen
Entwicklung maschineller Lernverfahren: Großer maschinenlesbarer EKG-Datensatz veröffentlicht
Mayo Clinic Minute: Health benefits of gardening
Study finds that aging neurons accumulate DNA damage
Local climate unlikely to drive the early COVID-19 pandemic
People with substance use disorders face greater challenges during the COVID-19 pandemic
Antibody designed to recognize pathogens of Alzheimer's disease
Vaccine hopes and economic woes as virus spreads
Problems with alcohol? 29 gene variants may explain why
Evolutionäre Zielkonflikte können die Entwicklung von Antibiotikaresistenzen nicht verhindern
Walking or cycling to work associated with reduced risk of early death and illness
COVID-19: Ulmer Forscher untersuchen in neuer Therapiestudie Wirkung von Ruxolitinib
Balanceakt: Gleichzeitige Bekämpfung von COVID-19 und den großen Volkskrankheiten
Virus could cut up to 9.7 percent off global economy: ADB
Russia reports record high daily virus death toll
COVID-19 and people with disabilities
Slovenia opens borders after declaring epidemic over
UK pledges June 1 rollout of contact-tracing amid criticism
Ten-year results display strong safety and efficacy profile for TPV device
Coronavirus may never go away: WHO
Parents that know a child's preferences can assertively guide exercise
Schulterschluss der Herzmedizin – Wir dulden keinen Rassismus
MCC: Städtische Umweltzonen senken Ausgaben für Herztabletten und Asthmasprays
UK PM Johnson backs key aide over lockdown breach claims
Pregnant and lactating women with COVID-19: Scant clinical research
Leberkrebs: Forderung nach mehr Aufmerksamkeit in Bezug auf Hepatitis D
How should I clean and store my face mask?
Coronavirus reminds you of death—and amplifies your core values, both bad and good
SARS-CoV-2 geht an die Nieren – welche therapeutischen Konsequenzen sind zu ziehen?
Cavity-causing bacteria assemble an army of protective microbes on human teeth
Study reveals mental health of medical personnel working with COVID-19 patients
Knochenkrebs : Die Schwäche des Tumors
AbbVie schließt Übernahme von Allergan ab
AI successfully used to identify different types of brain injuries
Tackling alcohol harms must be an integral part of the nation's recovery from COVID-19
How mindfulness can help amid the COVID-19 pandemic
Americans and Europeans soak up the sun amid new rules
'COVID toes,' other rashes latest possible rare virus signs
No new virus deaths in Ireland for first time 10 weeks
Virologe Streeck wehrt sich gegen Vorwürfe: „Doof gelaufen“
Mit Hochdurchsatz gegen Krebs und COVID-19
New research shows that increasing number of lost pregnancies is linked to higher risk of developing...
Voluntary collective isolation is best response to COVID-19 for indigenous populations
MB-Online-Umfrage: Ärzte für behutsame Rückkehr zum Regelbetrieb
COVID-19 patients may have lower stroke rates than previously suggested
Krankheitserreger nutzen Stickstoffmonoxid bei der Schleimhaut-Besiedlung
Museums, hotels, bars to reopen in Madrid, Barcelona
Blood flow recovers faster than brain in micro strokes
US poised to ban travel from Brazil: White House aide
Cell therapy treatment for cardiac patients with microvascular dysfunction provides enhanced quality
Study highlights importance of emergency department in hospital readmissions
Leibniz-WissenschaftsCampus EvoLUNG erhält erneut Förderung
New urine testing method holds promise for kidney stone sufferers
New studies reveal extent and risks of laughing gas and stimulant abuse among young people
UK govt boosts vaccine funding as daily virus deaths fall
Coronavirus cases pass 5.25 million worldwide
California hospitals saw sharp drop in heart attacks during COVID-19 shutdown
Kein Nutzen von Hydroxychloroquin und Chloroquin
Germany kicks off as Europe eases curbs but virus marches on
Möglicher Übertragungsweg? Erstmals SARS-CoV-2 in Muttermilch nachgewiesen
Coronavirus befällt auch Nieren und andere Organe
Researchers collaboratively test mask effectiveness to fight spread of COVID-19
Neue App für Pollen-Allergiker - Biermann Medizin

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

New study confirms important clues to fight ovarian cancer

Wed May 20 , 2020
Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left – diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. Credit: Nephron /Wikipedia. CC BY-SA […]